title: Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases.
abstract: Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement.
authors.affiliation: Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Aynur Pekcanlar
authors.initials: AP
authors.lastname: Akay
authors.affiliation: Department of Nuclear Medicine, Dokuz Eylul University Medical Faculty, Izmir, Turkey ; Department of Pediatrics, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Gamze Capa
authors.initials: GC
authors.lastname: Kaya
authors.affiliation: Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Burak
authors.initials: B
authors.lastname: Baykara
authors.affiliation: Department of Nuclear Medicine, Dokuz Eylul University Medical Faculty, Izmir, Turkey ; Department of Pediatrics, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Demir
authors.affiliation: Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Handan
authors.initials: H
authors.lastname: Özek
authors.affiliation: Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Sevay
authors.initials: S
authors.lastname: Alsen
authors.affiliation: Department of Nuclear Medicine, Dokuz Eylul University Medical Faculty, Izmir, Turkey ; Department of Pediatrics, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Mine Sencan
authors.initials: MS
authors.lastname: Eren
authors.affiliation: Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Neslihan Inal
authors.initials: NI
authors.lastname: Emiroglu
authors.affiliation: Department of Nuclear Medicine, Dokuz Eylul University Medical Faculty, Izmir, Turkey ; Department of Pediatrics, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Turkan
authors.initials: T
authors.lastname: Ertay
authors.affiliation: Department of Child and Adolescent Psychiatry, Abant İzzet Baysal University, Bolu, Turkey.
authors.forename: Yesim
authors.initials: Y
authors.lastname: Ozturk
authors.affiliation: Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Suha
authors.initials: S
authors.lastname: Miral
authors.affiliation: Department of Nuclear Medicine, Dokuz Eylul University Medical Faculty, Izmir, Turkey ; Department of Pediatrics, Dokuz Eylul University Medical Faculty, Izmir, Turkey.
authors.forename: Hatice
authors.initials: H
authors.lastname: Durak
authors.affiliation: Department of Child and Adolescent Psychiatry, Abant İzzet Baysal University, Bolu, Turkey.
authors.forename: Evren
authors.initials: E
authors.lastname: Tufan
keywords: SLC6A3 protein; dopamine; human; neuroimaging; noradrenaline; pilot study; pragmatic clinical trial